Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803037 | 0.92 | PLA2G2A (0.34) | PLA2G2ACRHR1MAPT | |
| SCHEMBL6797287 | 0.91 | PLA2G2A (0.33) | PLA2G2ACRHR1MAPT | |
| SCHEMBL6797803 | 0.90 | PLA2G2A (0.33) | PLA2G2ACRHR1 | |
| SCHEMBL6795930 | 0.82 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL6793450 | 0.76 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL5844009 | 0.76 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL6799331 | 0.75 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL6801679 | 0.74 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL5844156 | 0.74 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL6804329 | 0.73 | CRHR1 (0.41) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | PLA2G2A 2286/4885CRHR1 3/4885SMN1; SMN2 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.